Cytostatic treatment of glomerular diseases. V. Treatment of glomerulonephritis with cyclophosphamide plus prednisone, azathioprine plus prednisone and cyclophosphamide as monotherapy. A comparative study. A report from a Copenhagen Study Group of Renal Diseases.

Acta medica Scandinavica Pub Date : 1988-01-01
M Brahm, J T Balsløv, M Brammer, C Brun, J Gerstoft, H E Jørgensen, A Kamper, S Larsen, I Lorenzen, A C Thomsen
{"title":"Cytostatic treatment of glomerular diseases. V. Treatment of glomerulonephritis with cyclophosphamide plus prednisone, azathioprine plus prednisone and cyclophosphamide as monotherapy. A comparative study. A report from a Copenhagen Study Group of Renal Diseases.","authors":"M Brahm,&nbsp;J T Balsløv,&nbsp;M Brammer,&nbsp;C Brun,&nbsp;J Gerstoft,&nbsp;H E Jørgensen,&nbsp;A Kamper,&nbsp;S Larsen,&nbsp;I Lorenzen,&nbsp;A C Thomsen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Thirty-two patients suffering from biopsy-proven glomerulonephritis with proteinuria greater than or equal to 1.2 g/24 hours and/or creatinine clearance less than 50% of normal value were treated for 6 weeks with prednisone plus cyclophosphamide (C+P), azathioprine (A+P) or cyclophosphamide as a monotherapy (C). The effect of the treatment was evaluated after 6 and 16 weeks. The results were entered consecutively in a sequential analysis. The three treatment regimes were compared mutually as well as with the results of 16 weeks' treatment with C and placebo, published previously. Six weeks' treatment with C+P or A+P was superior to C and at least as efficient as 16 weeks' C treatment. C treatment for 6 weeks was less efficient than 16 weeks' C treatment. The side-effects of the 6 weeks' A+P or C+P treatment were fewer and less serious than those reported from the long-term C treatment.</p>","PeriodicalId":7011,"journal":{"name":"Acta medica Scandinavica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Scandinavica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Thirty-two patients suffering from biopsy-proven glomerulonephritis with proteinuria greater than or equal to 1.2 g/24 hours and/or creatinine clearance less than 50% of normal value were treated for 6 weeks with prednisone plus cyclophosphamide (C+P), azathioprine (A+P) or cyclophosphamide as a monotherapy (C). The effect of the treatment was evaluated after 6 and 16 weeks. The results were entered consecutively in a sequential analysis. The three treatment regimes were compared mutually as well as with the results of 16 weeks' treatment with C and placebo, published previously. Six weeks' treatment with C+P or A+P was superior to C and at least as efficient as 16 weeks' C treatment. C treatment for 6 weeks was less efficient than 16 weeks' C treatment. The side-effects of the 6 weeks' A+P or C+P treatment were fewer and less serious than those reported from the long-term C treatment.

肾小球疾病的细胞抑制剂治疗。五、环磷酰胺联合强的松、硫唑嘌呤联合强的松、环磷酰胺单药治疗肾小球肾炎。比较研究。一份来自哥本哈根肾脏疾病研究小组的报告。
32例活检证实的肾小球肾炎患者,蛋白尿大于或等于1.2 g/24小时和/或肌酐清除率低于正常值的50%,用强的松加环磷酰胺(C+P)、硫唑嘌呤(A+P)或环磷酰胺作为单药治疗(C)治疗6周,在6周和16周后评估治疗效果。结果在序列分析中连续输入。这三种治疗方案相互比较,并与先前发表的C和安慰剂治疗16周的结果进行比较。6周的C+P或A+P治疗优于C治疗,至少与16周的C治疗一样有效。C治疗6周的疗效低于C治疗16周。6周的A+P或C+P治疗的副作用比长期C治疗的副作用少且不严重。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信